(Abstracted from Urogynecology 2024;30:467–475 In 2013, the American Urogynecologic Society (AUGS) Board of Directors distributed a “Position Statement on Restriction of Surgical Options for Pelvic Floor Disorders” in response to limitations instituted by the US Food and Drug Administration (FDA) on the use of transvaginal mesh (TVM) for pelvic organ prolapse (POP) due to concerns about safety and effectiveness. This article is an update to that statement informed by additional clinical data, decisions from the FDA, and relevant guidelines regarding surgical mesh.
No takes yet. Share an insight, caveat, or question.
Lowder et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: